Phase I and Phase II Therapies for Acute Ischemic Stroke: An Update on Currently Studied Drugs in Clinical Research

Table 2

This table summarizes the thrombolytic drugs, details of clinical trials completed in AIS, route (i.v.: intravenous; i.a.: intra-arterial), phases, number of patients enrolled, and clinical trial number.

Summary of thrombolytic drug trials
Drug	Dose	Time window	Phase	Number of patients	Clinical trial number	Citation
Reteplase + abciximab	0.25 mg/kg bolus of abciximab i.v. + 0.125 mcg/kg/min infusion for 12 hours; i.a. reteplase in boluses of 0.25 units (5 minutes) proximal to the thrombus + incremental doses	3–6 hours after symptom onset	1	20	FDA Protocol Number 9180	[9]
Tenecteplase	0.25 mg/kg tenecteplase; 0.1 mg/kg tenecteplase; 0.9 mg/kg alteplase	6 hours after symptom onset	2b	75	New Zealand Clinical Trials Registry: ACTRN12608000466347	[10]
Tenecteplase	0.25 mg/kg tenecteplase; 0.9 mg/kg alteplase	4.5 hours after symptom onset	2	104	NCT01472926	[11]